This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery. Patients undergoing ureteroscopic tumor resection will receive 5-ALA prior to surgery, and surgeons will use special blue light to help identify abnormal tissue that might not be seen under standard white light. The goal is to assess whether this technique can enhance tumor detection and removal.
Patients aged 18 or older undergoing diagnostic or therapeutic ureteroscopy for a known or suspected upper tract urothelial tumor
Able to provide informed consent
Able to comply with study requirements
Known porphyria or hypersensitivity to porphyrins
Pregnant or breastfeeding women
AST or ALT > 2x upper limit of normal within 30 days prior to surgery
Participation in another investigational study within 30 days